Substitute for form 1449A&B/PTO						Complete if Known		
						Application Number	10/589,067	
I)	NFOR	MAT	TON DIS	CLOS	URE	Filing Date	March 30, 2007	
STATEMENT BY APPLICANT (Use as many sheets as necessary)						First Named Inventor	Garren, Hideki	
						Art Unit	1654	
						Examiner Name	Not Yet Assigned	
Sh	eet	1		of	1	Attorney Docket Number	021686-000910US	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	AA	BORNSTEIN, Murray B. et al.; "A Pilot Trial of COP 1 in Exacerbating-Remitting Multiple Sclerosis"; 1987, The New England Journal of Medicine, Vol. 317, No. 7, pp. 408-414.					
	AB	DUDA, Petra W. et al.; "Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis"; 2000, <u>The Journal of Clinical investigation</u> , Vol. 105, No. 77, pp. 967–976.					
	AC	FRIDKIS-HARELI, Masha et al.; "Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis"; 2002, The Journal of Clinical Investigation, Vol. 109, No. 12, pp. 1635-1643.					
	AD	WEBB, C. et al.; "Molecular Requirements Involved in Suppression of EAE by Synthetic Basic Copolymers of Amino Acids", 1976, lmmunochemistry , Vol. 13, pp. 333-337.					

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant or unique catation designation number (potional). *Applicant or to place a check mark here if English language Translation is attached.